At a glance
- Originator Aventis
- Developer Aventis; Nonindustrial source
- Class Anti-inflammatories; Nucleosides; Small molecules
- Mechanism of Action Adenosine A3 receptor agonists; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus; Rheumatoid arthritis
Most Recent Events
- 07 Jan 2004 No development reported - Preclinical for Rheumatoid arthritis in USA (unspecified route)
- 08 Oct 2001 No-Development-Reported for Diabetes mellitus in Sweden (Unknown route)
- 22 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma